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Summary
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD), are genetically linked to
host pathways that implicate an underlying role for aberrant immune responses to intestinal
microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent
among published studies. Using samples from multiple gastrointestinal locations collected prior to
treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to
date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae,
Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in
Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status.
Microbiome comparison between CD patients with and without antibiotic exposure indicates that
antibiotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial
signatures between the ileum, rectum, and fecal samples indicates that at this early stage of
disease, assessing the rectal mucosa-associated microbiome offers unique potential for convenient
and early diagnosis of CD.
Introduction
Inflammatory bowel disease (IBD) is a complex disease in which genetic and environmental
circuits establish and contribute to disease pathogenesis. Recent large-scale genome-wide
association studies link IBD to host-microbe pathways central to sensing/signaling and
mucosa-initiated effector responses (Jostins et al., 2012). Studies of the intestinal gut
microbiota imply that an unbalanced microbial community composition is associated with a
dysregulated immune response (Khor et al., 2011). The microbiome thus likely plays a role
in the pathogenesis of IBD (Manichanh et al., 2012), but this role remains poorly
understood. Previous studies characterized patients with established disease, but the use of
small cohorts resulted in a lack of statistical power to accommodate diverse clinical
covariates (Papa et al., 2012), and results of these studies were likely affected by the
application of treatments (Morgan et al., 2012). The existing new-onset studies that examine
the fecal microbiome (Kaakoush et al., 2012) detected a disease signal; however, because
fecal bacterial ecosystems differ from those in the intestinal mucosa (Momozawa et al.,
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2011), studies of strictly fecal communities may face limitations in identifying microbes
more directly involved in disease initiation or progression.
To improve our understanding of how the microbiota contributes to the inflammatory
cascade of Crohn’s disease (CD) pathogenesis, we performed a study that addresses several
important limitations of previous work. We applied a standardized approach to a large,
multicenter cohort of new-onset CD, collecting samples before treatment initiation, and
including subjects representing the variety of disease phenotypes with respect to location,
severity, and behavior. Here we report on 668 patients that include those with CD and non-
IBD controls (Table S1A), representing the largest single cohort microbiome study related to
new-onset IBD to date as well as representing the largest characterization of mucosal-
associated microbiota in non-IBD subjects. We used a combination of next-generation
sequencing to deeply characterize the disease-associated microbiota, and a well-established
multivariate analysis method to account for a wide range of demographic and clinical
covariates (e.g., age, gender, race, disease severity, behavior, and location) (Morgan et al.,
2012). The strength of this study lies in the sampling prior to treatment, the size of the
cohort, and the concurrent sampling of different sites, including multiple mucosal tissue
sites, and the luminal content as stool samples. Finally, we combined two additional cohorts
with the RISK cohort, resulting in a total of 1,742 samples from pediatric or adult patients,
with either new-onset or established disease, for which tissue biopsies and/or fecal samples
were processed through a uniform sequencing and analysis approach. This multi-cohort
study allows us to position the unique RISK cohort in the context of a comprehensively
defined diversity landscape of IBD, and to identify robust and generally applicable
biomarkers.
Results
A unique treatment-naïve inception cohort for pediatric CD
We studied the mucosal- and lumen-associated microbiota in a large, well-characterized
inception cohort for CD in children. We included subjects from 3 to 17 years of age with a
well-established diagnosis of CD (n = 447), and control subjects (n = 221) with non-
inflammatory conditions, for example presenting with abdominal pain and diarrhea (Table
S1A). Mucosal tissue biopsies (terminal ileum and rectum) and serum samples were
collected as part of the diagnostic colonoscopic examination prior to the initiation of
treatment. A subset of the enrolled patients (n = 233) also provided a fecal sample prior to
treatment start. The diagnosis and disease categorization was confirmed after a minimum of
six months follow-up, and was based on a combination of endoscopic, histological, and
radiological investigations. A total of 1,321 samples, including 630 ileal and 387 rectal
tissue biopsies and 304 stool samples, were submitted for microbiome profiling using 16S
rRNA gene sequencing on the Illumina MiSeq platform (version 2) with 175 bp paired-end
reads. After quality filtering and assembling overlapping paired-end reads, more than 45.5
million sequences were retained (mean of 29,915 sequences per sample), providing the most
in-depth characterization of treatment-naïve CD associated communities to date.
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The key players of the microbial dysbiosis in new-onset pediatric CD
An unweighted UniFrac-based comparison of the mucosal-associated microbiota from
patients with new-onset CD and controls indicated that the overall diversity in microbial
composition was mainly differentiated by sample type and microbial diversity, but disease
phenotype was not strong enough to differentiate patients (Figure 1A). Instead, complex
microbial communities from samples with multiple clinical covariates are best explored by
multivariate association tests at the level of specific microbial community members. We
identified microbial organisms that reached statistically significant association with subjects’
disease phenotype using the MaAsLin pipeline, which identifies significant associations of
the microbiota with multiple, potentially confounded sample variables (see Experimental
Procedures). This has the benefit of testing for disease characteristics, while controlling for
several known or potential confounding variables, such as past antibiotic use, age, gender,
and race. Correction for other factors that typically have a significant impact on the
microbial composition, including treatment and disease duration, was not necessary because
all samples were collected prior to treatment and at standard intestinal sites regardless of the
segments involved in the disease.
Biomarker detection analysis of mucosal-associated microbiome showed that inflammatory
conditions were most strongly associated with an overall drop in species richness and an
alteration in the abundance of several taxa (Figure 1B, Table S2A). Several of these taxa
have been reported in previous studies (Papa et al., 2012; Morgan et al., 2012), including
Enterobacteriaceae, Bacteroidales, and Clostridiales. However, we were able to identify
additional taxa as significant biomarkers for disease. Most noticeably, we detected positive
correlations between CD and abundances of Pasteurellaceae (Haemophilus sp.),
Veillonellaceae, Neisseriaceae, and Fusobacteriaceae. Fusobacterium has previously been
suggested as a biomarker for IBD (Strauss et al., 2011), and was also recently shown to
promote a beneficial microenvironment for the progression of colorectal carcinoma (Kostic
et al., 2012), a long-term complication of IBD. Subsampling the dataset to either smaller
sample sizes or lower sequencing depths indicated that sample size contributes more
substantially to the increased statistical power, highlighting the importance of sampling a
large cohort. Lowering the number of sequences to 300 reads/sample (~1% of the data) did
not affect our ability to detect these taxa (results not shown), but reducing to half of the
samples or lower did begin to affect the recovery of some taxa (Figure S1A). Interestingly,
few of these taxa were present at a higher abundance in patients under the age of 10, and
were thus negatively correlated with age, including Pasteurellaceae and Neisseriaceae (Table
S2A, Figure S1B).
An increased level of Bacteroides and Clostridiales was maintained in non-CD patients
relative to those with CD (Table S2A). Specific negative associations with CD were
detected for several genera, including Bacteroides, Faecalibacterium, Roseburia, Blautia,
Ruminococcus, Coprococcus, and a number of taxa within the families of Ruminococcaceae
and Lachnospiraceae. A well-described anti-inflammatory organism that is considered to be
a sensor and marker of health is Faecalibacterium prausnitzii (Sokol et al., 2008). Reduced
ileal abundance of F. prausnitzii has been associated with a higher rate of endoscopic
recurrence of inflammation six months after ileo-cecal resection.
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New-onset mucosal-associated dysbiosis is only weakly reflected in stool
The imbalance in the microbial community network was only observed in the microbiome
profiles obtained from tissue samples, and was not seen in the stool samples collected at the
time of the diagnosis (Figure 1B). This was confirmed by performing separate biomarker
detection on the stool samples of CD patients and controls with non-inflammatory
conditions, resulting in only a short list of taxa significantly associated with disease. This
included a gain in Streptococcus and a loss in a few taxa belonging to the order of
Clostridiales, including Dorea, Blautia, and Ruminococcus (Table S2B). With a mean
abundance far below 0.1%, all of these taxa were minimally contributing to the overall shift.
Consequently, we further investigated the precise differences between the mucosal tissue
and stool samples within patients with new-onset CD (Figure S1C, Table S2C). Of the four
above-mentioned taxonomic groups that were decreased in CD, all except Bacteroidales
were found to be significantly increased in stool samples, along with Lactobacillus,
Enterococcus, and Streptococcus. In addition, the levels of Fusobacteriaceae and
Neisseriaceae were reduced, but no significant differences were noted for any of the other
organisms typically associated with inflammatory conditions. Based on these observations,
we can infer that the microbial balance is less shifted towards a dysbiotic state in the lumen
despite the disease, explaining the lack of a biomarker signal and emphasizing the need to
examine tissue biopsies in addition to stool samples in order to gain a better understanding
of possible mechanisms.
Antibiotic exposure amplifies the microbial dysbiosis
Antibiotic usage has previously been linked to substantial taxonomic changes in the
gastrointestinal microbial composition (Dethlefsen et al., 2008; Antonopoulos et al., 2009;
Manichanh et al., 2010). Here, a small subset of the CD patients (n = 57 / 447, 13%) was on
antibiotics during sample collection, allowing a comparison between the microbiome in CD
patients with and without antibiotic exposure. Although a weak effect on disease severity
(PCDAI) and overall species diversity between the patient groups with and without
antibiotics was found (p = 0.043 and 0.02, respectively; Student’s t-test), we observed a
strong effect on the microbial composition, and exposure to antibiotics generally amplified
the dysbiosis. A more extreme impact was seen on the abundance levels of the phyla
increased in non-inflammatory conditions, including Bacteroides, Clostridiales, and
Erysipelotrichaceae, which was most pronounced in rectal biopsy and stool samples, with a
differential effect depending on taxa and sample type, e.g., a ten-fold increase in
Fusobacteriaceae in the ileum and Enterobacteriaceae in the rectum (Figure 1B). The
Pasteurellaceae were suppressed in the ileum, whereas the Veillonellaceae were decreased in
the rectum and stool. We note that excluding samples from subjects with antibiotics
exposure during sampling does not change the key players of the dysbiotic state outlined
above (Table S2A’). These results do not provide any causative explanation, but are relevant
in the context of previously described associations between higher antibiotic exposure and
the diagnosis of CD (Hviid et al., 2011). We hypothesize that the use of antibiotics has the
potential to impact the overall community structure and increase the potential for exposure
to dysbiosis.
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The functional dysbiosis at the mucosal tissue sites reflects that of established disease
Shotgun-sequencing for metagenomics would provide the greatest precision of microbial
community assays and direct evidence of microbial function. However, nucleotide extracts
of mucosal tissue samples consist of extremely high fractions (>99%) of host-derived
nucleotides. In the absence of methods to efficiently dissociate the microbial from the host
fraction, no cost-effective shotgun sequencing of the microbial communities can be
performed. Therefore, we predicted the functional composition of these mucosal-associated
microbiota using PICRUSt (Langille et al., 2013) (Table S2D). This algorithm estimates the
functional potential of microbial communities given a marker gene survey and the set of
currently sequenced reference genomes with an accuracy of 80-90% on human gut
communities. The functional changes in the samples of new-onset CD patients included a
loss in basic biosynthesis (related to reductions in Bacteroides and Clostridia) and a switch
towards pathobiont-like auxotrophy (increase in aerobic or aerotolerant taxa, i.e.,
Proteobacteria and Pasteurellaceae). Further, biomethanation was replaced by acetogenesis
in order to reduce accumulated hydrogen. An increased disease severity amplified the
disease signal of oxidative stress and auxotrophy further. Interestingly, components of the
benzoate metabolic pathway were associated with disease (Aminobenzoate degradation) and
disease severity (Fluorobenzoate degradation). Intermediaries of benzoate metabolism are
known to influence microbial dysbiosis as a stress response (Eloe-Fadrosh and Rasko, 2013)
and have the ability to promote Enterobacteriacea growth and virulence (Freestone et al.,
2007). Antibiotic exposure had several overlapping effects on the functional composition of
the gut microbiota and took up one third of all significant associations, including a unique
series of pathways related to xenobiotic metabolism (degradation of aminobenzoate, styrene,
chloroalkene, toluene, benzoate, etc.).
Describing disease status with the Microbial Dysbiosis index
We inferred a taxon-taxon interaction network for the ileal samples (see Experimental
Procedures) and found novel relationships among disease-associated organisms mentioned
above (Figure 2A, Table S2E). Out of all significant interactions found, 52% supported a
cooccurrence within the two groups of taxa that behave similarly with respect to disease,
i.e., increase or decrease in CD respectively, and 30% supported a strong co-exclusion
between these two groups. Importantly, the taxa within the families Enterobacteriaceae,
Fusobacteriaceae, Pasteurellaceae, and Veillonellaceae were often found together, as well as
different taxa within the Clostridia or Clostridia and Bacteroidetes teaming up with one
another. These observations led us to calculate the log of [total abundance in organisms
increased in CD] over [total abundance of organisms decreased in CD] for all samples,
hereafter referred to as the Microbial Dysbiosis index (MD-index). This MD-index, derived
on disease phenotype, showed a strong positive correlation with clinical disease severity
(PCDAI) (Figure 2B) and negative correlation with species richness (Figure 2C),
demonstrating that a severe disease state manifests a strongly reduced species diversity in
favor of a more extreme dysbiosis. Further, this index was a straightforward feature
capturing the overall beta-diversity, resulting in a clear gradient by which samples group
across all sample types (Figure 2D). This gradient reflects shifts in both groups of
organisms, those increased and decreased with disease (Figure S2B). Lastly, the MD-index
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was also significantly higher in those patients positive for two or more microbial or cytokine
serological markers (p < 0.0001, Student’s t-test). Since serologic markers are increasingly
being used to help differentiate IBD disease phenotypes, such an association might indicate
a potential link between the gut microbial biomarkers and the presence of these serologic
biomarkers. However, with the data collected for this cohort, no specific correlations were
found.
CD is characterized by inflammation spanning multiple tissue layers, with deep ulcer
formation linked with worse long-term disease outcomes. The RISK cohort measured deep
ulceration during the diagnostic colonoscopy, presenting us with the opportunity to examine
a link between the gut microbiota and mucosal ulceration. The recorded prevalence of any
deep ulcers (ileum or colon) with CD patients amounted to 42% (Table S1A). In those
patients, we observed increased levels of Pasteurellacaea and Veillonellaceae (p < 0.01,
FDR corrected p < 0.15) and Rothia mucilaginosa (p = 0.0004, FDR corrected p = 0.02). In
addition, an association between the KEGG pathway for pathogenic Escherichia coli
infection was positively associated with ulcer formation (Table S2D). Further experimental
study will be needed to determine whether any of these organisms are causally involved in
ulceration in IBD patients, or merely adapted to live in this affected environment.
Shotgun metagenome-based identification of microbial biomarkers
Most published studies of the microbiome in IBD so far have used a 16S rRNA gene-based
approach, and are thereby limited in characterizing the microbiota to a resolution at the
family/genus level. To study the microbiota at a higher resolution, a subset of 43 stool
samples (10 controls and 33 subjects) were shotgun-sequenced for metagenomics using the
Illumina HiSeq2000 platform (mean 13.3 gigabases (Gb) and s.d. 2.5 Gb per sample, paired-
end reads, fragment insert size 180b). Metagenomic data were filtered for human and low-
quality reads, and further analyzed as described in Experimental Procedures. As indicated
above, the stool samples of patients do not reflect the dysbiosis in a similar way as the
mucosal tissue samples, a finding that we confirmed at both the taxonomic and functional
levels with these data (results not shown). Nevertheless, mucosal-associated organisms were
not restricted to any particular intestinal location, and were readily observed in all sample
types, although at lower abundances. Therefore, by adding metagenomics data on the subset
of stool samples, we were able to profile the composition of microbial communities at a
finer taxonomic resolution (Table S2F). The dominant species increased in CD were
Escherichia coli, Fusobacterium nucleatum, Haemophilus parainfluenzae (Pasteurellaceae),
Veillonella parvula, Eikenella corrodens (Neisseriaceae), and Gemella moribillum. The
dominant species decreased in CD were Bacteroides vulgatus, Bacteroides caccae,
Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis,
Bifidobacterium dentum, Blautia hansenii, Ruminococcus gnavus, Clostridium nexile,
Faecalibacterium prausnitzii, Ruminoccus torques, Clostridium bolteae, Eubacterium
rectale, Roseburia intestinalis, and Coprococcus comes.
This detailed information and availability of genomic data will be useful in further
functional characterization of these organisms and their roles in disease pathogenesis. In a
first exploration, we performed a comparison between representative reference genomes for
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each of these species, generating a view of the differential KEGG pathways (Figure 3). The
species increased in CD uniquely contributed pathway components of glycerophospholipid
and lipopolysaccharide metabolism, found to instigate inflammation (Morita et al., 1999),
and phosphonoacetate hydrolase, providing access to a novel carbon and phosphate source
not accessible to most other organisms (Kim et al., 2011). Interestingly, the latter is a zinc-
dependent enzyme that might contribute to a mineral deficiency common in newly
diagnosed IBD patients. The pathway components unique to the species decreased in CD
contribute to the bile acid and amino acid biosynthesis pathways, including connections
between amino acid metabolism and energy, carbohydrate, or nucleotide metabolism.
Collectively, these provide access to complex carbohydrates, and the break at the alpha-
ketoglutarate step of the TCA cycle is indicative of a true anaerobic lifestyle, as indicated
previously (Morgan et al., 2012).
Biopsy-associated microbiome can diagnose CD
Several recent studies have explored the potential for identifying disease states based on the
host-associated microbial composition, including skin swabs for psoriasis (Statnikov et al.,
2013), and fecal samples for obesity (Le Chatelier et al., 2013), autism (Hsiao et al., 2013),
or IBD (Papa et al., 2012). Here, we evaluated how the microbiome composition in three
different sample types performed for classifying subjects by CD state using a receiver
operating characteristic (ROC) analysis. We included a total of 425 tissue biopsies of the
ileum, 300 of the rectum, and 199 stool samples in three independent analyses (Figure 4A-
C). Microbiome profiles were collapsed to the genus-level abundances and normalized (see
Experimental Procedures). The best performance was obtained by the ileal samples (AUC =
0.85), which was closely followed by the rectal biopsies (AUC = 0.78), both with a narrow
confidence interval. The stool samples, however, performed less well (AUC = 0.66) and had
also a low consistency (broader confidence interval). A previous study was able to get a
higher performance with stool samples for disease classification in an IBD cohort (Papa et
al., 2012), but their patient cohort distinguishes itself from RISK by the fact that subjects
had a mean disease duration of 34.8 months, and RISK cohort is entirely new-onset, with
samples only taken at the time of diagnosis. This finding is consistent with the biomarker
detection analysis that indicated that several taxonomic groups were increased or decreased
between cases and controls when comparing mucosal-associated microbiome profiles, but
not in stool samples (Figure 1). Interestingly, classification of subjects by disease state was
not affected by disease location. In this cohort, 22% had disease confined to the ileum, 25%
to the colon, and 53% had ileocolonic disease. Samples from both tissue biopsy locations
could classify subjects, even if disease was confined to the other location. In fact,
microbiome composition between the different biopsy sites was found to be far less different
than between tissue and stool, for all three disease sub-phenotypes (Figure 4D).
Further, this cohort presented the opportunity to derive a predictive model for future disease
outcome, as patients with a positive diagnosis for CD were re-examined at a 6- and 12-
month follow-up, at which point the disease activity index (PCDAI) was determined. For all
patients with such follow-up data available (n = 305), 7.5% had an increased disease
severity 6 months after diagnosis, and for 22% the severity reduced from severe (PCDAI >
30) to remission (PCDAI < 10). No tissue samples were collected at later time points, and
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thus no follow-up mucosal microbiome profiles exist. However, we could evaluate a model
for predicting whether a patient will develop an exacerbated or reduced disease severity over
the next 6 months, using the microbiome and clinical covariates collected at the time of
onset of disease. Using a random forests classifier trained on 90% of the data, we found we
were able to predict high 6-month PCDAI (≥ 10) in the remaining 10% of the data with
67.0% accuracy, a 14% improvement over the predictive accuracy of a model trained only
on clinical covariates (52.9 +/- 0.4%) (Figure S3A). Although the absolute level of accuracy
is modest, the performance gain driven by the microbiome is a direct and unbiased
demonstration of the utility of microbiome features for predicting clinical outcomes. To
determine how influential a given feature was in building the predictive model, we tested the
decrease in accuracy of the model when that feature was removed. The most influential
features for predicting future PCDAI according to this test were age of onset, PCDAI at
diagnosis, and levels of disease-associated organisms, including Enterobacteriaceae,
Fusobacterium, and Haemophilus. Age of onset and levels of Enterobacteriaceae were
negatively correlated with future PCDAI, and PCDAI at diagnosis and levels of
Fusobacterium and Haemophilus were positively correlated with future PCDAI (Figure
S3B).
Comparing pediatric CD with other adult established disease cohorts
To position the above findings in the context of other IBD microbiome studies, we
resequenced samples from a previously published study (Morgan et al., 2012) and included
samples from several other cohorts, using the same sequencing approach. Combining all of
these samples resulted in data from more than 1,500 subjects, of whom 46% had CD, 31%
had ulcerative colitis (UC), and 19% were non-IBD controls, and included both tissue
biopsies (88%) and stool samples (12%) (Table S1B). Two important differences between
the RISK cohort participants and the other cohorts were (i) the lower age range (13 yrs, s.d.
3, versus 41 yrs, s.d. 15), and (ii) the fact that RISK exclusively enrolled patients with new-
onset disease, whereas the mean disease duration at time of sampling in the other cohorts
was 7 years since diagnosis (s.d. 11, range 0 to 62). The combined dataset consisted of
nearly 60 million paired-end 16S reads, with a mean of 23,620 filtered sequences per
sample.
To our knowledge, this is the largest uniformly generated microbiome dataset for CD
specifically, but also IBD in general, revealing an extensive landscape of microbial diversity
across a wide range of subjects and disease phenotypes. We therefore took the opportunity
to examine the effect size of disease phenotype on the microbiome composition relative to
the effects introduced by cohort, age, gender, treatment, and biopsy location. We surveyed
effects on the biodiversity as a whole, and on the organisms contributing to the dysbiosis
specifically, and used a linear mixed effects model including cohort and subject as random
factors (see Experimental Procedures). The results revealed that inter-individual variation,
cohort and sample type had significant effects on the overall microbial community
composition, and that variation introduced by disease phenotype and treatment were hidden
underneath those primary factors (Table S2G). However, within specific sample types (e.g.,
terminal ileum), disease can explain up to 10% of the variation seen in subsets of key
dysbiotic taxa, in which the effects of having CD versus control do surface. The earlier
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described impact of antibiotics on the microbial community network was one of the stronger
signals across all cohorts, and found in almost all included sample types. Interestingly, the
signal was stronger in the mucosal-associated microbiome profiles than in the stool samples
(Figure S2A). In contrast, the impact of antibiotics on overall microbial diversity was
stronger in stool than in mucosal samples, again indicating that conclusions may differ based
on which sample types are studied. Taken together, this advocates for a need to standardize
sample collection, include diverse sample types to represent different gastrointestinal
compartments, and account for treatment effect in order to get the most statistical power to
study the role of the microbiome in diseases.
Lastly, we aimed to determine the effect on individual taxa using a biomarker detection
approach and compare the results across the different cohorts and disease phenotypes. Most
of the organisms that were found to be increased in CD were also found to be significantly
correlated with UC, but those taxa that were negatively associated with CD were not found
to be significant in association with UC (Table S2H). When using a weighted UniFrac
distance calculation and a PCoA visualization (Figure 5), the clustering by overall microbial
community composition was strongly affected by cohort (Figure 5B) and different disease
subgroups significantly overlapped (Figure 5A). However, the MD-index (Figure 5C) and
species richness (Figure 5D) still explained the first principal coordinate even when the
different cohorts were combined and demonstrate that the specific disease-associated taxa
were consistent.
Discussion
Our results on the microbiome at the onset of CD have identified the key constituents of the
complex gut microbial community that define a mucosal surface in homeostasis or
dysbiosis. Our work demonstrates that the creation of such a large multi-center cohort
increases the resolution and statistical power for studying the role of the microbiome in
disease. Several of the taxa we identified were only reliably associated with disease
phenotype when using several hundreds of samples. Achieving similar sample sizes by
combining independent cohorts for a cross-study comparison limits the study of parameters
with large effect size that surpass the bias introduced by differences in collection and sample
handling (Lozupone et al., 2013). Capturing microbial shifts in their full complexity,
including taxa with smaller shifts in relative abundance comparing cases versus controls,
require these large, optimal study designs.
Several of the organisms identified in this study are known to reside at the inflamed mucosa
with the potential to exacerbate inflammation and/or invade intestinal epithelial cells,
including strains of Escherichia (Rolhion and Darfeuille-Michaud, 2007) and
Fusobacterium (Strauss et al., 2011). Others, such as Haemophilus and Veillonella, have
recently been reported to contribute to oral dysbiosis in IBD patients (Said et al., 2013).
Haemophilus spp., like the Enterobacteriaceae, are well adapted to survive in oxidative
stress environments and intensify oxidative stress in airway infections (Harrison et al.,
2012). Interestingly, Veillonella spp. are closely related to the Clostridiales, who are
otherwise considered to be beneficial to the host (Furusawa et al., 2013). Prior literature,
however, indicates that Veillonella produce lipopolysaccharides (Gupta, 2011), a gene
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cluster they might have gained through horizontal gene transfer (Michael Fischbach,
personal communication). Rothia mucilaginosa, here reported at increased levels in patients
with intestinal ulcer formation, has been found to act as an opportunistic pathogen in
immunocompromised patients (Chavan et al., 2013) and has a genomic content that is well
adapted to live within the microaerophilic surface of the mucus layer in cystic fibrosis lungs
(Lim et al., 2013). Most of these organisms are relatively rare in the colon, and typically part
of the normal human oral and upper respiratory tract microbiota, but could become
opportunistic colonizers in conditions of altered mucosal changes in tissue oxygenation and
disruption of mucosal barrier function.
We observed that both the ileal and rectal biopsy have similar discriminatory power for
classifying disease, regardless of the disease location. This creates the opportunity to use a
minimally invasive sampling approach that avoids bowel preparation prior to the
colonoscopy, and to perform dense sampling of the mucosal-associated microbiome to
monitor the response to treatment and potentially predict changes in disease flares. Being
able to account more readily for the microbiota in larger cohort sizes will be of value in
defining disease sub-phenotypes and tracking treatment effects in clinical trials, something
that is currently not annotated. Understanding the microbial communities of the small
intestine remains of tremendous value. Mucosal-associated microbes are uniquely positioned
to influence the immune system (Belkaid and Naik, 2013); particularly, the porous mucus
layer in the ileum has been shown to educate the immune system to develop tolerance
towards commensals (Shan et al., 2013).
Large-scale collection of stool samples would be an even less invasive approach, but for this
cohort did not reflect the mucosal dysbiosis, in contrast to an earlier study (Papa et al.,
2012). The main difference between the two cohorts is that new-onset patients were sampled
at the time of diagnosis. The earlier study included samples of patients with established
disease (mean of 3 years at time of sampling) and a treatment history. We observed that the
microbial community associated with the inflamed epithelium had an increased level of
aerobic and facultative anaerobes (e.g., Protebacteria), whereas obligate anaerobes prevailed
in the feces (e.g., Bacteroides and Clostridiales). The microbial community in stool from
patients with established disease also consists of less anaerobes (Papa et al., 2012). This is
consistent with a recent observation that the oxygen level in the lumen increases with
intestinal inflammation to a level that gut microbiota start to shift towards an aerotolerant
composition in response to an oxidative stress (Mimouna et al., 2011). In order to validate
this observation, future work will need to consistently capture samples from patients across
a wide range of disease durations.
Another factor affecting the gut microbial composition is the use of antibiotics, as shown in
a subset of the RISK cohort patients. Previously, antibiotics have been claimed to provide
benefits for CD patients as a first-line therapy. However, we question this practice based on
our observation that the microbial network appears more dysbiotic in the context of
antibiotic exposure. Loss of protective microbes has the potential of triggering a
proliferation of less beneficial taxa (Looft and Allen, 2012), exacerbating the inflammation.
Similarly, changing dietary patterns can introduce such shifts as quickly (Wu et al., 2011),
particularly in those individuals with reduced microbial complexity (Fang and Evans, 2013).
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For example, the vitamin D pathway has importance in gut homeostasis and in signaling
between the microbiota and the host immune system, and may thus have implications for the
development, severity, and management of inflammation (Mouli and Ananthakrishnan,
2014).
The data presented here provide a unique framework for understanding the microbial
dysbiosis in new-onset CD. This will further develop principles that are likely to govern
therapeutics in IBD, but will need to be carefully thought through (Fischbach et al., 2013).
These include in particular those efforts that aim to shift the microbiome following a path
that is based on the successful principles applied to recurrent Clostridium difficile infections,
as these are unlikely to be directly applicable to the multifactorial disease pathogenesis of
IBD.
Experimental Procedures
Study population and sample collection
A total of 447 children and adolescents (< 17 years) with newly diagnosed CD and a control
population composed of 221 subjects with non-inflammatory conditions of the
gastrointestinal tract were enrolled to the RISK study in 28 participating pediatric
gastroenterology centers in North America between November 2008 and January 2012
(Table S1A). Biopsies were taken from the terminal ileum and rectum using standard
endoscopic forceps, and placed into a sterile cryovial with RNAlater (Qiagen) on ice in the
Endoscopy Suite. Nucleotides were isolated from these biopsies using the Qiagen AllPrep
Mini Kit.
16S rRNA gene sequencing
The 16S gene dataset consists of sequences targeting the V4 variable region. Detailed
protocols used for 16S amplification and sequencing are as previously described (Caporaso
et al., 2012). Sequencing was performed on the Illumina MiSeq platform according to the
manufacturer’s specifications with addition of 5% PhiX, and generating paired-end reads of
175b in length in each direction. The overlapping paired-end reads were stitched together
(approximately 97bp overlap), and further processed in a data curation pipeline implemented
in QIIME 1.7.0 as pick_closed_reference_otus.py (Caporaso et al., 2010). All 16S rRNA
sequences have been deposited at the National Center for Biotechnology Information as two
BioProjects with ID PRJNA237362 and PRJNA205152, and are also available in a variety
of tables through www.microbio.me/qiime/under Study ID 2516.
Shotgun metagenomic sequencing
Metagenomic data production and processing were performed as described previously
(HMP Consortium, 2012). In brief, library construction was performed on the Illumina
HiSeq 2000 platform, targeting 7 Gb of sequence per sample with 101bp, paired-end reads.
Species abundances were calculated with MetaPhlAn 1.7.7 (Segata et al., 2012), following
Bowtie 2-2.1.0 alignment (Langmead and Salzberg, 2012) to the MetaPhlAn 1.0 unique
marker database.
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Statistical analysis
Association testing of all covariates versus all taxa was performed by regressing the relative
abundance of each taxon on these linear clinical covariates: subject, diagnosis, ulcering, ileal
involvement, PCDAI, biopsy location, age, gender, race, antibiotic exposure, with subject as
a random variable, using the MaAsLin algorithm with default parameters (Morgan et al.,
2012).
Correlation network
We extracted the subnetworks of microbial interactions at the terminal ileum from subjects
free of any antibiotics pressure, using CCREPE (Compositionality Corrected by
REnormalization and PErmutation). This is a statistical methodology for co-variation
analysis in compositional data developed on top of previously published work (Faust et al.,
2012), using the NC-score, a similarity measure specifically designed to detect association
patterns in the human microbiome and other microbial communities (see Supplemental
Information).
ROC analysis
ROC curves were constructed to evaluate the performance of sparse logistic regression
classifier (using L1 penalization) aiming to identify the IBD status of a subject based on his
or her microbiome profile. We have checked the performance for classifier trained by
samples from three different sites (ileum, rectum, and stool). Five ROC curves were gained
per site using 5-fold cross-validation. A mean ROC curve was then given by averaging over
all 5 individual fold ROC curves and an approximated 95% pointwise confidence interval
was also constructed by using normal approximation and the sample means and variances.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Microbiomes from multiple GI locations in new-onset Crohn’s disease (CD)
cases analyzed
• Co-occurring and co-excluded CD-associated organisms identified
• Rectal mucosa-associated, but not fecal, microbiome is a robust disease
predictor
• Antibiotics amplify the dysbiosis associated with CD
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Figure 1. Most differential taxa in pediatric CD
(A) A set of principal coordinate plots of the unweighted UniFrac distance, with each
sample colored either by the disease phenotype (left), alpha diversity (middle), or sample
type (right). PC1, PC2, and PC3 represent the top three principal coordinates that captured
most of the diversity, with the fraction of diversity captured by that coordinate shown in
percent. (B) Differences in abundance are shown for the taxonomic biomarkers that were
detected using a multivariate statistical approach (see Experimental Procedures and Table
S2). The fold change for each taxon was calculated by dividing the mean abundance in the
cases by that of the controls. Several taxonomic biomarkers measured at both the ileal and
rectal sites were found to be significantly correlated with disease phenotype; however, most
of that microbial signal was lost in the stool samples. The fraction of patients that were on
antibiotics during sample collection was considered as an individual subtype, due to the
large confounding impact antibiotic exposure causes on the microbial composition (see
Table S2). The left shows cases without antibiotic treatment, and the right includes the
fraction of cases (10%) that were under antibiotic pressure at sampling. The taxa at the top
are increased in disease state, whereas the taxa at the bottom follow an opposite trend.
Apparent missing bars are cases in which there is no difference, or fold change equals 1. Use
of antibiotics does impact the microbial composition by tipping the microbial community
further towards a dysbiotic state, and has a differential impact on the taxa, depending on
organism and sampling site. Related to Figure S1, Table S1.
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Figure 2. The Microbial Dysbiosis index characterizes CD severity
(A) A correlation network was inferred for the ileal microbiota compositions using CCREPE
with a checkerboard score, indicating a strong co-occurrence between taxa of the same
disease-associated behavior and a co-exclusion between taxa of a different behavior. Nodes
represent the different taxa, and color corresponds to their behavior in disease, with green
for those decreased in CD and red for those increased in CD. Edges between nodes represent
correlations between the nodes they connect, with edge colors of dark and light grey
indicating positive and negative correlations, respectively. For clarity, only edges
corresponding to correlations whose similarity was less than 0.3 are shown. (B) Scatterplot
of the arcsine square root transformed abundances of all summed abundances for the taxa
increased (top) or decreased (bottom) in CD, versus the pediatric CD activity index (PCDAI
(Hyams et al., 1991)) as a measure for disease severity. (C) Scatter density plot of the
species richness (Chao1, (Chao et al., 2006)) versus the Microbial Dysbiosis index (MD-
index) for each sample. The increase in blue color (white to dark blue) reflects the density of
the scatter plot. The MD-index is defined as the log of [total abundance in organisms
increased in CD] over [total abundance of organisms decreased in CD] (organisms listed in
Fig 1A), and is intended as an overall summary statistic for the microbial dysbiosis
described in more detail in panel A. In samples with a high MD-index (> 1), a strong
reduction in the species richness was observed. (D) A principal coordinate plot of the
unweighted UniFrac distance, colored by the MD-index. Sqrt, square root.Related to Figure
S2, Table S2.
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Figure 3. Comparative genomics of CD biomarkers
The KEGG metabolic pathways that differentiate the species by behavior in disease state are
shown as a heatmap. A selection of reference genomes that are representative for the species
increased or decreased with disease were obtained from IMG (JGI), and biomarker detection
was performed on their gene content at the level of KEGG pathways. Several were
statistically significant (Wilcoxon, p < 10e-8) and are visualized here. Related to Table S2.
Gevers et al. Page 20
Cell Host Microbe. Author manuscript; available in PMC 2015 March 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Disease classification performs well on biopsy-associated microbiome profiles
(A-C) For each of the three sample types, including terminal ileum biopsy (A), rectum
biopsy (B), and stool sample (C), we evaluated the accuracy of disease classification using
L1 penalized logistic regression with ROC curves representing the results. Dashed lines
show the mean performance obtained when genus-level features were used, and the
surrounding grey area is the 95% confidence interval. Terminal ileum biopsies performed
best (AUC = 0.85), closely matched by the rectum biopsies (AUC = 0.78). However, the
classifier based on the stool samples collected at the time of the diagnosis performs less well
(AUC = 0.66), and with low consistency (large confidence interval). (D) The intra-subject
diversity in microbiome composition was determined for all pairwise sample type
combinations. Both biopsy samples were found to be highly similar, whereas the stool
sample was quite diverse. Further, we also compared whether disease location would impact
the intra-subject diversity between the two tissue biopsy locations. The location of the
disease, ileal (L1), colonic (L2), or ileocolonic (L3), did not significantly disrupt the
similarity between the two intra-subject mucosal-associated microbiota. Also, no biomarker
was detected allowing us to distinguish these disease sub-phenotypes. Related to Figure S3.
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Figure 5. A view of the microbial composition across different IBD cohorts
We combined microbial profiles obtained for 1,742 subjects from three different IBD
cohorts and generated a set of principal coordinate plots of the unweighted UniFrac distance,
where each sample was colored by (A) cohort, (B) disease type, (C) MD-index, or (D)
species richness (Chao1). From this combined view, it is clear that the first principal
coordinate (PC1) stratifies the samples by species richness, which is negatively correlated
with MD-index, and that the second principal coordinate (PC2) is largely affected by cohort.
Disease phenotype is no obvious driver for sample clustering.
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